{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:14:17Z","timestamp":1778865257771,"version":"3.51.4"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"DOI":"10.7759\/cureus.108914","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:53:02Z","timestamp":1778863982000},"source":"Crossref","is-referenced-by-count":0,"title":["Atezolizumab-Associated Autoimmune Diabetes Presenting as Diabetic Ketoacidosis in a Woman With Hepatocellular Carcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Itizaz","family":"Hayat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajid","family":"Hayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taimoor","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Loo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn RS","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al.. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020, 382:1894-905. 10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-233842","article-title":"Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma","volume":"13","author":"Rahman W","year":"2020","unstructured":"Rahman W, Conley A, Silver KD. Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma. BMJ Case Rep. 2020, 13:10.1136\/bcr-2019-233842","journal-title":"BMJ Case Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.57024","article-title":"Atezolizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer and pre-existing type 2 diabetes mellitus","volume":"16","author":"Narumoto K","year":"2024","unstructured":"Narumoto K, Oda N, Mitani R, Takata I. Atezolizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer and pre-existing type 2 diabetes mellitus. Cureus. 2024, 16:e57024. 10.7759\/cureus.57024","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0860-22","article-title":"Development of fulminant type 1 diabetes mellitus in the course of treatment with atezolizumab for hepatocellular carcinoma","volume":"62","author":"Ikeda M","year":"2023","unstructured":"Ikeda M, Tamada T, Takebayashi R, et al.. Development of fulminant type 1 diabetes mellitus in the course of treatment with atezolizumab for hepatocellular carcinoma. Intern Med. 2023, 62:1775-9. 10.2169\/internalmedicine.0860-22","journal-title":"Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-250662","article-title":"Atezolizumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis and Takotsubo cardiomyopathy","volume":"15","author":"Singhal S","year":"2022","unstructured":"Singhal S, Patel G, Singh RB, Goyal A, Avgush K, Koka J. Atezolizumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis and Takotsubo cardiomyopathy. BMJ Case Rep. 2022, 15:10.1136\/bcr-2022-250662","journal-title":"BMJ Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4688-24","article-title":"Hepatocellular carcinoma complicated by fulminant type 1 diabetes mellitus shortly after initiation of durvalumab plus tremelimumab","volume":"64","author":"Usui N","year":"2025","unstructured":"Usui N, Imai Y, Sugawara K, et al.. Hepatocellular carcinoma complicated by fulminant type 1 diabetes mellitus shortly after initiation of durvalumab plus tremelimumab. Intern Med. 2025, 64:2143-7. 10.2169\/internalmedicine.4688-24","journal-title":"Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/491286-atezolizumab-associated-autoimmune-diabetes-presenting-as-diabetic-ketoacidosis-in-a-woman-with-hepatocellular-carcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:53:02Z","timestamp":1778863982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/491286-atezolizumab-associated-autoimmune-diabetes-presenting-as-diabetic-ketoacidosis-in-a-woman-with-hepatocellular-carcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.108914","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}